Timothy Rolph, Chief Scientific Officer at Akero Therapeutics, Inc. (AKRO), sold 23,134 shares at $52.00 ($1.2M) on 2025-07-07, disclosed to the SEC on 2025-07-09.
Scheduled sale ($1.2M) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $50.93 | 10,634 | $542K | 45.9% |
| 2 | $50.93 | 10,634 | $542K | 45.9% |
| 3 | $52.00 | 1,825 | $95K | 8.0% |
| 4 | $52.62 | 41 | $2K | 0.2% |
| Total | $51.02 avg | 23,134 | $1.2M | 100% |
| Filing → |
| AKRO | SELL | 2025-09-10 | $1.1M | — | Filing → |
| AKRO | SELL | 2025-08-07 | $1.2M | — | Filing → |
| AKRO | SELL | 2025-06-20 | $124K | — | Filing → |